Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis

Medicine and Dentistry

• Migraine 100%
• Post-Hoc Analysis 100%
• Contraindication 100%
• Triptan Derivative 100%
• Lasmiditan 100%
• Triptan 50%
• Boron Neutron Capture Therapy 33%
• Cardiovascular System 16%
• Placebo 16%
• Analgesia 16%
• Receptor 16%
• Vasoconstriction 16%
• Drug Megadose 8%
• Subgroup Analysis 8%
• Symptom 8%
• Pooled Analysis 8%
• Controlled Clinical Trial 8%
• Somnolence 8%
• Patient-Data 8%
• Dizziness 8%

Keyphrases

• Migraine 100%
• Triptans 100%
• Lasmiditan 100%
• Spartan 30%
• Pain Relief 20%
• Vasoconstriction 20%
• 5-HT1B Receptor 20%
• Samurai 20%
• Treatment Options 10%
• High Dose 10%
• Tolerability 10%
• Placebo 10%
• Low Affinity 10%
• Pooled Analysis 10%
• Randomized Placebo-controlled Trial 10%
• Subgroup Analysis 10%
• Migraine Attack 10%
• Disability 10%
• Severe Intensity 10%
• Somnolence 10%
• Trial Registration 10%
• Receptor Agonist 10%
• Patient Data 10%
• As(V) 10%
• Electronic Diary 10%
• Dizziness 10%
• Moderate Intensity 10%
• Efficacy Data 10%
• Patient Subgroups 10%
• Pain Freedom 10%
• 5-HT1F Receptor Agonist 10%
• Patient Global Impression of Change 10%
• Most Bothersome Symptom 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Migraine 100%
• Triptan Derivative 100%
• Lasmiditan 100%
• Placebo 22%
• Receptor Agonist 22%
• Symptom 11%
• Tolerability 11%
• Controlled Clinical Trial 11%
• Somnolence 11%
• Dizziness 11%